| Product Code: ETC9551607 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Sweden Clinical Oncology NGS Market Overview |
3.1 Sweden Country Macro Economic Indicators |
3.2 Sweden Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F |
3.3 Sweden Clinical Oncology NGS Market - Industry Life Cycle |
3.4 Sweden Clinical Oncology NGS Market - Porter's Five Forces |
3.5 Sweden Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Sweden Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Sweden Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Sweden Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Sweden Clinical Oncology NGS Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Sweden |
4.2.2 Growing adoption of personalized medicine in oncology |
4.2.3 Technological advancements in next-generation sequencing (NGS) technology |
4.3 Market Restraints |
4.3.1 High costs associated with NGS testing |
4.3.2 Limited reimbursement policies for NGS tests in clinical oncology |
4.3.3 Data privacy and security concerns related to genomic data |
5 Sweden Clinical Oncology NGS Market Trends |
6 Sweden Clinical Oncology NGS Market, By Types |
6.1 Sweden Clinical Oncology NGS Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Sweden Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Sweden Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Sweden Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Sweden Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F |
6.2 Sweden Clinical Oncology NGS Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Sweden Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F |
6.2.3 Sweden Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F |
6.2.4 Sweden Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F |
6.3 Sweden Clinical Oncology NGS Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Sweden Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Sweden Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Sweden Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F |
6.4 Sweden Clinical Oncology NGS Market, By End-use |
6.4.1 Overview and Analysis |
6.4.2 Sweden Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Sweden Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Sweden Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F |
7 Sweden Clinical Oncology NGS Market Import-Export Trade Statistics |
7.1 Sweden Clinical Oncology NGS Market Export to Major Countries |
7.2 Sweden Clinical Oncology NGS Market Imports from Major Countries |
8 Sweden Clinical Oncology NGS Market Key Performance Indicators |
8.1 Average turnaround time for NGS testing in clinical oncology |
8.2 Percentage of oncology clinics in Sweden offering NGS testing services |
8.3 Number of clinical trials incorporating NGS technology in oncology research |
9 Sweden Clinical Oncology NGS Market - Opportunity Assessment |
9.1 Sweden Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Sweden Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Sweden Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Sweden Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F |
10 Sweden Clinical Oncology NGS Market - Competitive Landscape |
10.1 Sweden Clinical Oncology NGS Market Revenue Share, By Companies, 2024 |
10.2 Sweden Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here